EzriCare

EzriCare is a U.S.-based private healthcare company that markets and distributes over-the-counter ophthalmic products, most notably EzriCare Artificial Tears. The company appears to function primarily as a distributor/brand owner rather than a drug discovery or development biotech, and FDA records describe it as operating as a distributor of EzriCare's Artificial Tears manufactured by a contract manufacturer, Global Pharma Healthcare Private Limited. EzriCare became widely known following the 2023 nationwide recall of its artificial tears product associated with microbial contamination and a multistate outbreak of drug-resistant Pseudomonas aeruginosa infections. The company is not a therapeutics pipeline company and there is no evidence of proprietary R&D programs, clinical-stage assets, or a platform technology. Its business is best characterized as commercialization and distribution of consumer eye-care products in the U.S. market.